From Kratom to Semi‐Synthetic Opioids: The Rise and Risks of MGM‐15
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Abhishek Gour und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Mitragyna, Analgesics, Opioid, Secologanin Tryptamine Alkaloids, Morphine Derivatives. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: University of Florida Foundation, University of Florida College of Pharmacy, University of South Carolina.
Abstract (Originalsprache)
Kratom ( Mitragyna speciosa ), a plant native to Southeast Asia, has long been used for its stimulant and analgesic properties. 7‐Hydroxymitragynine (7‐HMG) is a potent and selective opioid agonist in vitro and demonstrates a potent opioid effect in living subjects, reversible by naloxone. It has been semi‐synthesized into products that are readily available in retail and virtual shops. It is known that 7‐HMG has earned the nickname “legal morphine,” and has gained popularity among users seeking pain relief and/or a “high” comparable with prescription opioids. Medicinal chemistry efforts have led to synthetic 7‐HMG derivatives such as MGM‐15, where stereospecific saturation of the imine N(1)–C(2) double bond increases opioid receptor affinity and activity. Despite its higher in vitro opioid potency, MGM‐15 is currently sold in the US for human consumption as a “research chemical” in tablet form, even though there is an absence of this being studied in humans and obviously no FDA approval. In this study, we analyzed commercially available MGM‐labeled tablets using UPLC–MS/MS and subsequently evaluated the binding affinities of purified MGM‐15 across multiple opioid receptors. Tablets contained an average of 10.9 ± 0.2 mg (10.7 to 11.2 mg) of MGM‐15, with no naturally occurring kratom alkaloids or illicit substances detected. MGM‐15 shows greater hMOR and hDOR binding affinities than 7‐HMG, indicating the potential for higher opioid effects and risks, emphasizing the urgent need for more research to advise regulation and hopefully prevent misuse and harm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Mississippi Poison Control Center, Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
- Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
- Translational Drug Development Core, Clinical and Translational Sciences Institute, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Abhisheak Sharma
Förderung
- University of Florida Foundation
- University of Florida College of Pharmacy
- University of South Carolina
Zitieren
APA
Gour, A., Mukhopadhyay, S., Henderson, A., Awad, A., Seabra, M. A., Pullman, M., León, F., Cutler, S. J., McCurdy, C. R., & Sharma, A. (2025). From Kratom to Semi‐Synthetic Opioids: The Rise and Risks of MGM‐15. Drug Testing and Analysis. https://doi.org/10.1002/dta.3952
Vancouver
Gour A, Mukhopadhyay S, Henderson A, Awad A, Seabra MA, Pullman M, et al. From Kratom to Semi‐Synthetic Opioids: The Rise and Risks of MGM‐15. Drug Testing and Analysis. 2025. doi:10.1002/dta.3952
BibTeX
@article{Gour2025,
author = {Gour, Abhishek and Mukhopadhyay, Sushobhan and Henderson, Allison and Awad, Ahmed and Seabra, Maria A and Pullman, Mallory and León, Francisco and Cutler, Stephen J and McCurdy, Christopher R and Sharma, Abhisheak},
title = {From Kratom to Semi‐Synthetic Opioids: The Rise and Risks of MGM‐15},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3952}
}
EUVIMED